Small Molecules that Correct RNA Splicing

At Skyhawk Therapeutics we use proprietary structural, kinetic, and computational models to invent small molecules that correct splicing in RNA, targeting some of the world's most intractable diseases

IN THE NEWS

Merck doubles down on Skyhawk's tech to drug RNA, promising

$600M per autoimmune, metabolic target

When Merck signed on to discover candidates against neurodegeneration and cancer last July, Biogen was just expanding the list of neuro targets they want to go after. Now Merck is coming back for its own round two, adding autoimmune and metabolic diseases to the menu.

The 20 under 40: Inside the next generation of biopharma leaders

U-2 Dragon Lady, one of the conference rooms at Skyhawk Therapeutics’ office in Waltham, MA, is named after both

the American single-jet engine, high altitude reconnaissance aircraft and founder Kathleen McCarthy.

Celgene execs shell out $92M cash for a pair of R&D deals that

will fit perfectly in their new home at Bristol-Myers

Celgene is shelling out $80 million in a cash upfront to add oncology, immuno-oncology and autoimmune diseases to the initial roundup of neurological targets mapped early in Skyhawk’s existence.

BOSTINNO

The 20 Startups to Watch in Boston in 2020

Based on factors like funding, partnerships, awards, technology licenses and more, we've worked to identify the startups that are on the precipice of something big. These companies, we think, will be making major moves to kick off the new Roaring 20s.

Skyhawk Therapeutics boosts Merck collab pact with added targets, upfront and biobucks

Merck has decided to double down on its research pact with startup Skyhawk Therapeutics as it expands the deal to now also cover autoimmune and metabolic diseases.

IN THE NEWS

Merck doubles down on Skyhawk's tech to drug RNA, promising

$600M per autoimmune, metabolic target

When Merck signed on to discover candidates against neurodegeneration and cancer last July, Biogen was just expanding the list of neuro targets they want to go after. Now Merck is coming back for its own round two, adding autoimmune and metabolic diseases to the menu.

The 20 under 40: Inside the next generation of biopharma leaders

U-2 Dragon Lady, one of the conference rooms at Skyhawk Therapeutics’ office in Waltham, MA, is named after both

the American single-jet engine, high altitude reconnaissance aircraft and founder Kathleen McCarthy.

Celgene execs shell out $92M cash for a pair of R&D deals that

will fit perfectly in their new home at Bristol-Myers

Celgene is shelling out $80 million in a cash upfront to add oncology, immuno-oncology and autoimmune diseases to the initial roundup of neurological targets mapped early in Skyhawk’s existence.

BOSTINNO

The 20 Startups to Watch in Boston in 2020

Based on factors like funding, partnerships, awards, technology licenses and more, we've worked to identify the startups that are on the precipice of something big. These companies, we think, will be making major moves to kick off the new Roaring 20s.

WHAT WE DO

Our proprietary small molecule platform targets accelerates the discovery and development of drugs that correct RNA mis-splicing across a broad range of disease types:

ONCOLOGY

NEUROLOGY

INFLAMMATORY

INFECTIOUS

RARE

NEUROMUSCULAR

& METABOLIC

LEARN MORE

Small Molecules that Correct RNA Splicing

PARTNERS

IN THE NEWS

IN THE NEWS

WHAT WE DO